文献速递类风湿关节炎

美国退伍军人类风湿关节炎患者接受免疫检查点抑制剂治疗的死亡率

Mortality in US Veterans With Rheumatoid Arthritis Treated With Immune Checkpoint Inhibitors.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-02-04

该研究比较了退伍军人健康管理局中接受免疫检查点抑制剂(ICI)抗癌治疗的类风湿关节炎(RA)患者与无RA对照的全因和病因特异性死亡率。结果共纳入301例RA患者和2,114例对照,RA组与对照组的全因死亡率风险比为1.08(95%CI 0.94-1.25,粗分析)和1.09(95%CI 0.94-1.25,校正分析),死因构成相似(肿瘤死亡RA组93.0% vs 非RA组90.9%,P=0.737)。结论认为RA患者接受ICI未出现死亡率增加或死因差异。

要点

  • RA患者接受ICI治疗的全因死亡率与无RA对照相比无显著差异(校正HR 1.09,95%CI 0.94-1.25)。
  • 两组死因构成相似,肿瘤为最常见死因(RA组93.0% vs 非RA组90.9%,P=0.737)。
  • 感染相关死亡在两组均罕见(<1.0%)。

核心结论

  • RA患者因恶性肿瘤接受ICI治疗,与无RA的ICI治疗患者相比,未出现死亡率增加或死因差异。

研究设计与样本

  • 研究在退伍军人健康管理局(VHA)中识别接受ICI治疗的RA患者,并按年龄、性别和VA入组年份匹配无RA对照,比较全因和病因特异性死亡率。
  • 共纳入301例RA患者和2,114例无RA对照,采用Cox模型、Kaplan-Meier曲线和log rank检验评估从ICI initiation起的生存。

主要发现

  • RA组与无RA对照组全因死亡率的粗HR为1.08(95%CI 0.94-1.25),校正HR为1.09(95%CI 0.94-1.25)。
  • 死亡原因两组相似,肿瘤为最常见死因,RA组93.0% vs 非RA组90.9%(P=0.737)。
  • 感染所致死亡在两组均罕见(<1.0%)。

关键数值与推荐

  • 全因死亡率粗HR 1.08(95%CI 0.94-1.25),校正HR 1.09(95%CI 0.94-1.25),RA组 vs 无RA对照组。
  • 肿瘤死亡比例RA组93.0% vs 非RA组90.9%(P=0.737)。
  • 感染死亡比例两组均<1.0%。

临床怎么用

  • 这些初步数据提示,基于个体患者情况,RA患者可考虑将ICI治疗作为癌症治疗的一部分。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This investigation compared all-cause and cause-specific mortality in patients with and without rheumatoid arthritis (RA) in the Veterans Health Administration (VHA) following immune checkpoint inhibitor (ICI) cancer treatment. METHODS: Veterans with RA and a control set of Veterans without RA who were matched on age, sex, and year of Veterans Affairs enrollment and had received an ICI were identified. All-cause and cause-specific mortality were obtained. Survival from the time of ICI initiation was evaluated using Cox models, Kaplan-Meier curves, and log rank testing. RESULTS: There were 301 patients with RA and 2,114 controls without RA treated with an ICI. The majority of the participants were white, male, and current/former smokers. Lung cancer was the most common malignancy (51.2%), pembrolizumab was the most frequently used ICI (43.9%), and most patients received ICI monotherapy (97.1%). Cox proportional hazard ratio comparison of all-cause mortality in patients with RA to controls without RA was 1.08 (95% confidence interval [CI] 0.94-1.25) for the crude analysis and 1.09 (95% CI 0.94-1.25) for the adjusted analysis. Cause of death was similar in the two groups, most frequently neoplasm in 93.0% and 90.9% for RA and non-RA groups, respectively (P = 0.737). Deaths due to infection were rare in both groups (<1.0%). CONCLUSION: Patients with RA who received ICIs for the treatment of malignancy did not experience increased mortality or differences in cause of death compared with patients without RA receiving ICIs. These preliminary data suggest ICI therapy may be considered as part of cancer treatment in RA patients based on individual patient circumstances.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. O'Sullivan ML, Cannon GW, Sauer BC, et al. Mortality in US Veterans With Rheumatoid Arthritis Treated With Immune Checkpoint Inhibitors. Arthritis Care Res (Hoboken). 2026. PMID: 41208804. doi:10.1002/acr.25691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。